Navigation Links
Opsona Therapeutics Closes EUR18M Funding
Date:2/18/2009

anised monoclonal antibody (OPN-305) to a key toll-like receptor (TLR) target, has demonstrated efficacy in a number of animal models and will start pivotal clinical trials in 2010.

Florent Gros, managing director, Novartis Venture Fund added, "We are delighted to be working with Opsona Therapeutics and the other investors to assist Opsona in progressing the company's highly innovative technology and approaches towards the clinic. The innate immune system represents a new frontier in targeting inflammatory diseases, and the caliber of the investors in this funding round is a demonstration of Opsona's expertise and capabilities in this highly promising field.'

Opsona has also announced the opening of a new facility in Switzerland. The Swiss laboratory will carry out pivotal assay development and biochemical work for new projects and therapeutics recently acquired by Opsona to expand its pipeline of immunomodulators. The expertise that it intends to grow in Switzerland will complement the existing team and activity in Dublin.

Dr Cormac Kilty, Chairman of Opsona and past Chairman of the Irish Bioindustry Association explains "This is major achievement for any biotechnology company in the current economic climate. Opsona's R&D shows that emerging Irish companies can reach international recognition in biotechnology."

Notes to Editors:

About Opsona Therapeutics

Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 with three of Trinity College Dublin's respected Immunologists (Professors Luke O'Neill, Kingston Mills and Dermot Kelleher). The company is specifically interested in drugs which modulate the innate immune system and its signalling, specifically Toll-Like Receptors (TLR). Opsona has a pipeline of therapeutics in advanced pre-clini
'/>"/>

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Office has announced the launch of several innovative new ... services in the current economic climate. The first ... to finance legal services over a period of 6, ... in their start-up companies. The second is aimed ... payment arrangements over 6 to 12 month period at ...
(Date:12/14/2009)... Vermillion, Inc. (Pink Sheets: VRML), a molecular ... Ph.D. Chief Scientific Officer, Senior Vice President, ... be joining its board of directors upon ... "Bill brings more than 20 years research ... said Gail Page, Vermillion Executive Chairperson. ...
(Date:12/14/2009)... Rep. Patrick Kennedy Joins with State Biotech ... Leadership in Research and Development while Boosting ... Industry ,, PROVIDENCE, R.I., Dec. 14 ... prominent leaders in research, medicine and biotechnology ... Facility to discuss the importance of medical ...
(Date:12/14/2009)... Dec. 14 Boston Scientific Corporation (NYSE: ... public offering of $2 billion aggregate principal amount of ... The public offering consists of $850 million of ... 6.00 percent notes due January 2020 and $300 million ... Scientific plans to use the net proceeds for general ...
Breaking Biology Technology:The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3
... ThermoGenesis,Corp.(Nasdaq: KOOL ), said today that it ... AXP(TM) AutoXpress Platform(TM) (AXP) bag sets., The Company ... that,some lots of the bag sets were distributed prior ... release criterion., The Company said that this recall ...
... Corporation,(Nasdaq: BPUR ) today announced its financial results ... the quarter, the company reported a net,loss of $5.8 ... net loss,of $6.9 million, or $0.53 per common share, ... outstanding on January 31, 2008 and 2007 were,34,971,087 and ...
... for fixed C-arms to grow over 5% annually over the ... years, according to Millennium Research Group, ... Global Markets for C-Arms 2008 report, the US market for,fixed ... was valued at over $1.4 billion in 2007 and will,rise ...
Other Biology Technology:ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets 2Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Fixed C-Arms Revolutionize Operating Room Environments 2
(Date:12/14/2009)... 2009If you are spending the holidays with big Uncle ... would be better off with another family, spare a ... research team from McMaster University and the University of ... species that lives in groups, members make strategic decisions ... in the current issue of Biology Letters . ...
(Date:12/14/2009)... as a defining feature of humans. That,s until examples of ... and an array of other mammals. Now, a report in ... Cell Press publication, adds an octopus to the growing list ... a behavioral trick that the researchers call stilt walking. In ... shell "bowls," makes its eight arms rigid, and raises the ...
(Date:12/14/2009)... MODA Technology Partners, a global software ... product testing for the Pharmaceutical industry, today announced ... third generation mobile data acquisition platform. The latest ... automate their regulated manufacturing processes. ,, MODA ... Fully-Configurable Test Methods: Each test method ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2Share the Passion Photography Exhibition 26 Red Carpet Gala 57280 1Share the Passion Photography Exhibition 26 Red Carpet Gala 57280 2Share the Passion Photography Exhibition 26 Red Carpet Gala 57280 3Neurocrine Biosciences Secures Committed Equity Financing Facility 14065 1Neurocrine Biosciences Secures Committed Equity Financing Facility 14065 2Neurocrine Biosciences Secures Committed Equity Financing Facility 14065 3Diabetes Medications Dont Lower Inflammation 57271 1Diabetes Medications Dont Lower Inflammation 57271 2Diabetes Medications Dont Lower Inflammation 57271 3
... 2009) Virginia Commonwealth University researchers have found that ... mitochondria, the energy-producing machines of cells. This discovery could ... for heart disease to boost energy in failing heart ... , In the study, published online Jan. 8 in ...
... http://www.biologists.com/ ) organises and supports a themed conference as the ... of Experimental Biology . The main aim of this annual ... varied expertise on one particular subject. It is a leisurely ... social side of science is also catered for an ...
... 28 , 2009 Genomatix Software announced today that ... the ongoing Illumina program and working with them to ... , Klaus May, Chief Business Officer for Genomatix Software ... of a complete NGS data analysis capability, we are ...
Other Biology News:Survival in a Changing World: The Journal of Experimental Biology 2009 symposium 2Genomatix joins Illumina-Connect program 2
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
... PGF2α is a metabolically stable ... a potent uterine stimulant and ... intramuscularly to induce labor. It ... progesterone concentrations when given as ...
... Mut S is a member of a class ... of the DNA sequence. Mut S plays an ... DNA ,replication, in transcription-coupled nucleotide excision repair and ... bacteria. Mut S binds to DNA specifically at ...
... (GSTs) are a group of enzymes important ... in mammals. The enzymes protect cells against ... the glutathione to electrophilic xenobiotics, and thereby ... toxic effects of the compounds. GST activity ...
Biology Products: